Full-Life raises $77 million to boost radiopharma pipeline
China-Belgium biotech Full-Life Technologies has raised $77 million through a mix of $50 million series C equity and $27 million debt financing. The cash will accelerate its radiopharmaceutical pipeline and fund completion of a manufacturing plant in Gembloux, Belgium. Total financing since its 2021 launch now approaches $200 million.
Junson Capital led the equity round, joined by Lapam Capital, Plaisance, TruMed Investment and others, alongside existing backers such as Chengwei Capital and Prosperity7. The debt portion offers flexibility for clinical development and early-stage programs, while also ensuring the Belgian facility comes online as planned.
The company is focused on radionuclide drug conjugates, especially actinium-225 based therapies. Its lead candidate, [225Ac]AC-FL-020, is in a global Phase I trial. New funds will also support fresh regulatory filings and early discovery work, reflecting continued investor confidence in tackling global isotope supply shortages.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze